- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approved April 2023).
- Why 3/10
- INVEGA HAFYERA is an already-approved, marketed drug with no pending regulatory decision or pivotal readout. For Alkermes, it is a royalty revenue stream, not a development asset. No hard binary catalyst exists in the next ~12 months. The royalty term expires in May 2030, which is beyond the 12-month window.
INVEGA HAFYERA has no upcoming binary catalyst for Alkermes because it is an already-approved, marketed drug generating royalties. The key date to watch is May 2030, when the royalty term expires and this revenue stream ends. For Alkermes, the more impactful near-term catalysts are its proprietary pipeline, including the ALKS 2680 orexin agonist program and LUMRYZ commercial execution.
Price Chart
Executive Summary
INVEGA HAFYERA (paliperidone palmitate) is a long-acting injectable antipsychotic for schizophrenia, dosed once every six months. It was developed and is marketed by Janssen Pharmaceuticals (Johnson & Johnson), not by Alkermes. Alkermes plc (Nasdaq: ALKS) receives royalties on global sales of INVEGA HAFYERA through a licensing agreement that runs through May 2030. The drug was FDA-approved on April 26, 2023. For Alkermes, this is a passive royalty revenue stream, not a development-stage asset. In Q3 2026, Alkermes reported $26.4 million in combined royalty revenue from the INVEGA product family (XEPLION, INVEGA TRINZA/TREVICTA, and INVEGA HAFYERA/BYANNLI).
How It Works
INVEGA HAFYERA is an atypical antipsychotic that works by blocking dopamine and serotonin receptors in the brain. It is a long-acting injectable formulation of paliperidone that is administered by a healthcare professional into the gluteal muscle once every six months, making it the longest dosing interval available for schizophrenia treatment.
Trial Status
INVEGA HAFYERA was FDA-approved on April 26, 2023 based on a 12-month Phase 3 non-inferiority study showing 92.5% of patients were relapse-free at 12 months versus 95% for INVEGA TRINZA (the every-three-month formulation). The drug is commercially available and marketed by Janssen.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalyst for INVEGA HAFYERA specifically. The royalty stream continues through May 2030 with no scheduled events.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alkermes plc. 8-K ALKS ·Originating report